Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Snyder Mark Drugs Roselle, Inc. d.b.a. Mark Drugs Pharmacy
WARNING LETTER
•Snyder Mark Drugs Roselle, Inc. d.b.a. Mark Drugs Pharmacy•May 22, 2017

Snyder Mark Drugs Roselle, Inc. d.b.a. Mark Drugs Pharmacy – FDA Warning Letter, May 22, 2017

Record Details

An FDA inspection of Mark Drugs Pharmacy (Snyder Mark Drugs Roselle, Inc.) from April 26 to May 22, 2017, revealed serious deficiencies in sterile drug product production and failure to meet Section 503A of the FDCA. The firm did not receive valid prescriptions for individually-identified patients for a portion of its compounded drugs, rendering them ineligible for exemptions from CGMP, adequate labeling, and FDA approval.

Violations included insanitary conditions, such as operators blocking unidirectional airflow, failing to sanitize gloves, wearing non-sterile gloves during aseptic production, and exposing sterile products to substandard air quality. The firm also failed to adequately monitor pressure differentials and demonstrate proper protection of ISO 5 areas.

For ineligible drug products, significant CGMP violations were cited, including failure to establish and follow procedures for preventing microbiological contamination (21 CFR 211.113(b)), ensure appropriate personnel clothing (21 CFR 211.28(a)), maintain equipment for aseptic conditions (21 CFR 211.42(c)(10)(vi)), monitor environmental conditions (21 CFR 211.42(c)(10)(iv)), conduct final product testing (21 CFR 211.167(a)), and establish stability testing programs (21 CFR 211.166(a)). These products are considered adulterated, un

Company
Snyder Mark Drugs Roselle, Inc. d.b.a. Mark Drugs Pharmacy
Inspection date
May 22, 2017
Product type
Drugs
Office
Detroit District Office
People
  • Art O. Czabaniuk (Program Division Director)
  • Nicholas F. Lyons (Director of Compliance)
  • Russell K. Riley (Investigator)
View Company Profile

ID · 8561cdbe-e9c3-4a8e-bc73-d386e8bdb63c

Violation Codes10
21 U.S.C. 321(g)21 U.S.C. 351(a)(2)(B)21 U.S.C. 353a21 U.S.C. 352(f)(1)21.U.S.C. 355(a)21 U.S.C. 331(k)21 U.S.C. 331(d)21 CFR 21021 CFR 21121 CFR 211.113(b)

Full citation text and observation details available on the Dashboard.

Other documents for Snyder Mark Drugs Roselle, Inc. d.b.a. Mark Drugs Pharmacy
  • 483 - 2019-09-27September 27, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Snyder Mark Drugs Roselle, Inc. d.b.a. Mark Drugs Pharmacy
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.